To bring the latest advancements in the treatment of eye cancer, Hyderabad’s LV Prasad Eye Institute (LVPEI) has signed an MoU with Antonia Champalimaud Foundation (ACF), Lisbon, Portugal. The MoU seeks to innovate pioneering eye cancer treatment solutions and allows for genetic, molecular and cellular analysis.
The MoU was signed by Dr Gullapalli N Rao, Founder-Chair, LVPEI, and Dr Leonor Beleza, President, ACF. The aim of this agreement is to prevent eye cancer which is most prevalent in children in India.
The collaboration is expected to bring new insights and therapeutic approaches to the problem of eye cancer (Retinoblastoma). 85% of childhood eye cancer can be cured.
Retinoblastoma occurs mostly between 0-4 years of age. India accounts for one fifth of total Retinoblastoma cancer cases across the globe.